clopidogrel hashtag on Twitter
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention - ScienceDirect
Stentless strategy in primary PCI setting: An alternative strategy in some clinical scenarios? - ScienceDirect
Dual Antiplatelet and Glycoprotein Inhibitors in Emergency PCI | SpringerLink
Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PEN
PDF) Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: An observational comparative study
Antithrombotic therapy for patients with STEMI undergoing primary PCI | Nature Reviews Cardiology
Management of patients after primary percutaneous coronary intervention for myocardial infarction | The BMJ
A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free
P2Y12 inhibitors during and after acute coronary syndrome, where do we stand in 2020?
Tailoring P2Y12 Inhibiting Therapy in Elderly Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention | Journal of the American Heart Association
Reloading patients chronically treated with P2Y12 inhibitors and presenting with ACS/PCI: Facing a crossroad? - International Journal of Cardiology
stemi
Poll Results: Preload With P2Y12 Inhibitor - American College of Cardiology
Proposed use of P2Y12 inhibitors - ppt download
Multivessel Versus Culprit-only Percutaneous Coronary Intervention in ST-segment Elevation Acute Myocardial Infarction: Analysis of an 8-year Registry | Revista Española de Cardiología (English Edition)
P2Y12 inhibitors during and after acute coronary syndrome, where do we stand in 2020?
Meta-Analysis of the Efficacy and Safety of Genotype-Guided Strategy for Selection of P2Y12 Inhibitors in Coronary Artery Disease - American Journal of Cardiology
Optimal pharmacological therapy in ST-elevation myocardial infarction—a review | SpringerLink
Antiplatelet therapy in coronary artery disease
P2Y12 inhibitors during and after acute coronary syndrome, where do we stand in 2020?
![PDF] A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a00275204b744cd63f1a792ad9748b856dc6bc2b/5-Figure1-1.png "PDF] A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. | Semantic Scholar")
PDF] A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. | Semantic Scholar
JCM | Free Full-Text | De-Escalation of Antiplatelet Treatment in Patients with Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Review of the Current Literature | HTML
Myo.infarction
Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI - International Journal of ...
PDF) Pre-treatment with P2Y12 inhibitors in ACS patients: Who, when, why, and which agent?
